2025-08-21 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the provided data, presented in English with a focus on key metrics and their implications.

## Merck & Co Inc (MRK) Stock Analysis

**Company Overview:** Merck & Co Inc is a global pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of a wide range of healthcare products.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** -21.41%
*   **VOO Cumulative Return:** 37.28%
*   **Absolute Deviation:** -58.69% (MRK is underperforming VOO by 58.69%)
*   **Relative Deviation:** -109.1 (Max: 23.1, Min: -111.0, Relative Deviation: 1.4)

**Analysis:** MRK has significantly underperformed the S&P 500 (VOO). The relative deviation, positioned near the lower end of its historical range, suggests that MRK's underperformance is near its worst relative to the S&P 500 over the period considered.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha | Beta  | Cap(B) |
|------------|-------|-------|-------|-------|--------|
| 2015-2017  | 0.0%  | 0.0%  | 0.0%  | 1.0   | 134.1  |
| 2016-2018  | 0.0%  | 0.0%  | 0.0%  | 1.0   | 182.1  |
| 2017-2019  | 0.0%  | 0.0%  | 0.0%  | 1.0   | 216.8  |
| 2018-2020  | 0.0%  | 0.0%  | 0.0%  | 1.0   | 195.0  |
| 2019-2021  | 0.0%  | 0.0%  | 0.0%  | -0.0  | 191.4  |
| 2020-2022  | 26.0% | 69.3% | 37.0% | -0.0  | 277.1  |
| 2021-2023  | 24.0% | 69.3% | 14.0% | -0.0  | 272.3  |
| 2022-2024  | -1.0% | 69.3% | -30.0% | -0.0  | 248.5  |
| 2023-2025  | -46.0% | 71.5% | -89.0% | -0.0  | 211.5  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Fluctuates significantly, with recent years showing negative growth.
*   **MDD (Maximum Drawdown):** Relatively high, indicating significant potential losses.
*   **Alpha:** Largely negative in recent periods, suggesting underperformance relative to the market on a risk-adjusted basis.
*   **Beta:** Close to zero, meaning that the return is un-correlated with the return of the S&P500.
*   **Cap(B):** Market capitalization of the company in billions.

### 2. Recent Price Action

*   **Current Price:** 84.66
*   **Previous Close:** 84.93
*   **Change:** -0.32
*   **5-day Moving Average:** 84.16
*   **20-day Moving Average:** 81.98
*   **60-day Moving Average:** 80.78

**Analysis:** The stock price is slightly down compared to the previous close. The price is trading above its 5-day, 20-day, and 60-day moving averages, indicating a short-term uptrend.

### 3. Technical Indicators

*   **MRI (Market Risk Indicator):** 0.3316 (Low Risk)
*   **RSI (Relative Strength Index):** 79.46 (Overbought)
*   **PPO (Percentage Price Oscillator):** 0.55
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.33)
*   **Delta of Relative Deviation (20-day):** 1.4 (Positive - Short-term increase)
*   **Expected Return (%):** -853.9% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI indicates a low-risk environment for the overall market.
*   The RSI is in overbought territory, suggesting the stock may be due for a pullback.
*   The positive change in relative deviation suggests short-term momentum may be improving.
*   The significantly negative expected return suggests that, based on the model, MRK is expected to significantly underperform the S&P 500 over the long term.
*   The recent price change of -0.32, while negative, is not significant enough to suggest any major volatility events.

### 4. Recent News & Significant Events

*   **August 19, 2025:** Major business developments, regulatory changes, or market events are impacting MRK.
*   **August 18, 2025:** Analysts are discussing MRK's performance in the context of industry trends and global economic factors.
*   **August 20, 2025:** MRK's stock shows notable volatility influenced by recent news, earnings, or executive actions.
*   **August 17, 2025:** Market experts highlight risks and opportunities, advising monitoring of news and announcements.

**Analysis:** Recent news suggests that MRK is experiencing significant activity, including potential regulatory changes or business developments impacting its stock.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-08-05 | 1.76 | 15.81 B$   |
| 2025-05-02 | 2.01 | 15.53 B$   |
| 2024-11-06 | 1.25 | 16.66 B$   |
| 2024-08-05 | 2.15 | 16.11 B$   |
| 2025-08-05 | 2.15 | 16.11 B$   |

**Analysis:** The EPS(Earning Per Share) are quite inconsistent. The revenue has shown a slight decline.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $15.81B    | 77.50%        |
| 2025-03-31   | $15.53B    | 77.98%        |
| 2024-12-31   | $15.62B    | 75.50%        |
| 2024-09-30   | $16.66B    | 75.51%        |
| 2024-06-30   | $16.11B    | 76.76%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE   |
|--------------|------------|-------|
| 2025-06-30   | $48.99B    | 9.04% |
| 2025-03-31   | $48.34B    | 10.51%|
| 2024-12-31   | $46.31B    | 8.08% |
| 2024-09-30   | $44.50B    | 7.09% |
| 2024-06-30   | $43.58B    | 12.52%|

**Analysis:**

*   **Revenue:** Revenue has fluctuated but remained relatively stable over the past five quarters.
*   **Profit Margin:** Consistently high, indicating strong profitability.
*   **Equity:** Increasing trend indicates growing shareholder value.
*   **ROE (Return on Equity):** Fluctuates but generally indicates good profitability relative to equity.

### 7. Overall Analysis & Summary

*   **Underperformance:** MRK has significantly underperformed the S&P 500.
*   **Technicals:** RSI suggests overbought conditions, potentially leading to a pullback.  Short-term momentum may be improving.
*   **Fundamentals:** Strong profit margins and generally positive revenue trends. Equity is growing.
*   **News:** Significant news events and analyst discussions are influencing the stock.
*   **Caution:** The significantly negative expected return warrants caution regarding long-term investment in MRK relative to the S&P 500, based on the model.
*   **Hybrid signal:** recommends buy 80% of cash, it should be considered very carefully because MRI value(0.33) is caution level.

**In summary, while MRK demonstrates good profitability and a low-risk market environment, its underperformance relative to the S&P 500 and the negative long-term expected return suggest that investors should proceed with caution.** The recent news events warrant careful monitoring.
